Spectrum yanks marketing application for Neulasta rival after FDA demands more data

Spectrum yanks marketing application for Neulasta rival after FDA demands more data

Source: 
Endpoints
snippet: 

Months after Spectrum Pharmaceuticals informed investors that the FDA had denied its lung cancer drug poziotinib the breakthrough therapy status tag, the drugmaker said it is rescinding the marketing application for its lead experimental drug to accommodate the US agency’s request for more manufacturing data.